Concepedia

Sam Khalil

SK

9

Publications

503

Citations

9

H-Index

1999

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Novartis (Japan)

Kobe University

Fujita Health University

Sam Khalil is an author at Novartis (Switzerland) specializing in medicine, allergy, and dermatology.

Top concepts

Publications per year

1999–2020

9

Publications

9

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

Allen P. Kaplan, Marta Ferrer, Jonathan A. Bernstein et al. · Journal of Allergy and Clinical Immunology · 2015 · 193 citations · Full text

Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study

Kelly Hollis, Christina Proctor, Doreen McBride et al. · American Journal of Clinical Dermatology · 2018 · 73 citations · Full text

Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria

Michihiro Hide, Hae‐Sim Park, Atsuyuki Igarashi et al. · Journal of Dermatological Science · 2017 · 66 citations · Full text

, , +6

Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis

Marta Ferrer, Ana M. Giménez‐Arnau, Diego Saldana et al. · The Journal of Allergy and Clinical Immunology In Practice · 2018 · 47 citations · Full text

Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial

Gordon Sussman, Jacques Hébert, Wayne Gulliver et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 38 citations

, , +6

Rows per page

1–5 of 9